The U.S. Food and Drug Administration (FDA) has issued final guidance on the transfer or sale of Premarket Notification 510(k) clearances between companies.
The final guidance, “Transfer of a Premarket Notification (510(k)) Clearance – Questions and Answers”, was issued on 20 November 2026, following a draft published on 5 June 2025.
The document addresses a practical regulatory question that can arise during acquisitions, divestitures, licensing arrangements and other business transactions involving FDA-cleared devices: when does the new holder of a transferred 510(k) need to submit a new 510(k)?
Transfer Alone Does Not Necessarily Trigger a New 510(k)
FDA confirms that when a 510(k) clearance for a specific device is sold or transferred from one person to another, the new holder does not need to submit a new 510(k) if the device has not been significantly changed or modified in:
design;
components;
method of manufacture;
intended use.
This is one of the central clarifications in the final guidance.
The transfer of ownership itself is therefore not, on its own, a trigger for a new premarket notification.
Significant Changes May Still Require a New Submission
The position is different where the transferred device is significantly changed.
FDA reiterates that a new 510(k) may be required where a device is significantly modified in:
design;
components;
manufacturing method;
intended use.
The usual FDA principles for determining whether a device modification requires a new 510(k) therefore continue to apply after a transfer.
Guidance Applies to Both Previous and New Holders
The guidance applies to both:
the previous 510(k) holder;
the new 510(k) holder.
It covers situations where a 510(k) clearance for a specific device has been sold or otherwise transferred from one person to another.
FDA Defines the 510(k) Holder as a Single Person
FDA defines a 510(k) holder as the singular person that possesses the 510(k) clearance for a device.
That holder may be a manufacturer, including a specifications developer.
The guidance later makes clear that FDA considers there to be only one 510(k) holder for a device at a time.
No Simultaneous 510(k) Holders
FDA explicitly addresses whether a device can have simultaneous 510(k) holders.
The answer is no.
FDA states that maintaining a single holder helps:
support compliance with applicable legal requirements;
improve tracking of signals and adverse events;
facilitate communication between sponsors and FDA.
New Holder Must Create a New Device Listing
Although a transfer may not require a new 510(k), it can still trigger important administrative obligations.
Where the new 510(k) holder performs activities that require device listing, it must create a new listing in FDA’s electronic device registration and listing system.
FDA’s system then assigns a new unique listing number to the new holder.
Original 510(k) Number Generally Remains Relevant
Where the device has not been significantly modified, the new holder should generally use the original FDA-assigned 510(k) premarket submission number when listing the device.
If a new 510(k) becomes necessary because of a significant device modification, the new submission number would instead be used after clearance.
Registration Timing for the New Holder
If the new holder was not already engaged in an operation requiring registration, it must generally register within 30 daysafter entering into that operation.
At that time, it must also submit the required device listing information, including the relevant FDA-assigned 510(k) submission number.
Annual Listing Obligations Continue
The new 510(k) holder must also comply with FDA’s recurring registration and listing obligations.
FDA states that during each fiscal year, between 1 October and 31 December, the holder must report new device listings that were not previously reported, including devices covered by newly acquired 510(k) clearances.
Registration and Listing Support Postmarket Oversight
The guidance explains why accurate listing information matters.
FDA may use its registration and listing system to identify manufacturers and other regulated entities during postmarket surveillance activities, including where rapid communication may be necessary for a recall.
For transferred devices, this reinforces the importance of ensuring that FDA records accurately reflect the current holder and responsible establishments.
Previous Holder Must Update Its Listing
When a 510(k) is transferred, the responsibilities of the previous holder do not necessarily end automatically.
If the previous holder stops performing an activity previously identified in the device listing, such as manufacturing, it must update that listing.
If it discontinues commercial distribution entirely, the device listing must be discontinued.
Contract Manufacturers and Other Entities
The guidance also clarifies which other entities may use the cleared 510(k) number when listing a device.
Entities required to list the cleared device may include:
contract manufacturers;
contract sterilizers;
repackagers;
relabelers.
These entities must use the FDA-assigned submission number of the cleared 510(k) when completing the applicable device listing.
Initial Importers Are Treated Differently
FDA notes that initial importers may satisfy their listing obligations by providing the name and address of the manufacturer, provided they did not:
initiate or develop the device specifications;
repackage the device;
relabel the device.
Labeling May Need to Be Updated
Transfer of a 510(k) clearance can also trigger labeling changes.
FDA notes that the sale or transfer may require updates to information such as:
manufacturer name;
packer name;
distributor name;
place of business.
Companies involved in a transaction should therefore assess labeling impacts as part of the transfer process.
UDI Requirements Continue to Apply
The guidance also reminds companies that device labels and packages are generally required to bear a Unique Device Identifier (UDI) where applicable.
This means that a change in 510(k) ownership may have consequences beyond registration and listing.
GUDID Records May Need Updating
Where information associated with the device changes as a result of the transfer, the labeler must update relevant information in the Global Unique Device Identification Database (GUDID).
Examples include changes to the identity of the labeler.
FDA states that updated information must generally be submitted when required under the applicable UDI regulations.
Failure to Update Records Can Have Regulatory Consequences
FDA warns that failure to:
register;
list;
update GUDID information;
submit a required marketing application
may result in the device being considered adulterated and/or misbranded.
This makes the administrative aspects of a 510(k) transfer a significant compliance issue.
FDA Does Not Automatically Update Its Databases After a Transfer
One particularly important clarification concerns notifications sent directly to FDA.
FDA states that it commonly receives notifications from individuals advising that a 510(k) has been transferred and requesting that FDA update its registration and listing databases.
However, FDA makes clear that it is the responsibility of the establishment owner or operator to satisfy the applicable registration and listing requirements.
FDA is not required to update its registration or listing information simply because it receives a transfer notification.
Practical Implication: The Transaction Itself Is Not Enough
From a regulatory perspective, completing the contractual transfer of a 510(k) does not automatically complete the FDA administrative transition.
The new holder may need to separately address:
establishment registration;
device listing;
use of the correct 510(k) number;
GUDID updates;
labeling;
UDI information;
relationships with contract manufacturers and other listed entities.
The previous holder may also need to update or discontinue its own listings.
Access to Historical 510(k) Records
The guidance also addresses how a new holder may obtain copies of the original 510(k) records.
FDA states that a company may:
request documents directly from the previous owner;
submit a Freedom of Information Act (FOIA) request.
CDRH also makes certain previously released 510(k) records available through its public 510(k) database.
M&A and Licensing Transactions Should Include Regulatory Due Diligence
The guidance is particularly relevant for:
mergers and acquisitions;
product divestitures;
asset purchases;
licensing arrangements;
corporate restructuring.
A transaction involving an FDA-cleared device should therefore include regulatory due diligence to determine:
whether the 510(k) itself is being transferred;
whether the device will remain unchanged;
who will become the sole 510(k) holder;
which establishments require registration;
which listings must be created or discontinued;
whether labeling or UDI information changes;
whether GUDID updates are required.
Important Distinction Between Ownership and Device Modification
One of the most useful aspects of the final guidance is the distinction between:
a change in ownership of the clearance, and
a significant change to the device itself.
The former does not necessarily trigger a new 510(k).
The latter may.
This distinction should be clearly documented as part of the regulatory transfer strategy.
Implications for Regulatory Affairs Teams
For regulatory teams, the final guidance provides a clearer framework for managing 510(k) transfers.
Key actions may include:
reviewing the transaction scope;
confirming device configuration remains unchanged;
evaluating whether a new 510(k) is required;
updating registration and listing records;
confirming the correct 510(k) number;
assessing labeling changes;
updating GUDID;
coordinating with contract manufacturers and sterilizers;
maintaining transfer documentation.
Implications for Quality and Postmarket Teams
The guidance also has implications beyond premarket regulatory affairs.
Accurate identification of the current holder supports:
complaint handling;
adverse-event tracking;
recalls;
postmarket surveillance;
FDA communications.
This is one reason FDA emphasises having a single identifiable 510(k) holder at any given time.
Final Guidance Replaces the 2025 Draft
The document history confirms that the guidance is now issued as Level 1 Final Guidance in November 2026, following the Level 1 Draft Guidance issued in June 2025.
The final publication therefore establishes FDA’s current recommended approach for handling transfers of 510(k) clearances.